Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352664 · ClinicalTrials.gov registry record · Phase 3
The Effect of Donepezil on Sedation and Other Symptoms
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT00352664: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00352664 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00352664, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To determine the effectiveness of donepezil as compared to placebo for the management of opiate-induced sedation/drowsiness in patients with stable cancer pain Secondary Objectives: 1. To assess the side-effects in both groups of 1 week treatment of 5 mg donepezil and placebo 2. To assess the effects of donepezil on fatigue (FACIT-Fatigue), and other symptoms (Anderson Symptom Assessment Scale) 3. To assess the effects of donepezil on cognition (Symbol Digit Modalities Test) 4. To assess the effects of donepezil on constipation (number of bowel movements)
Interventions
- DRUG Placebo
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352664
The ClinicalTrials.gov registry entry for NCT00352664 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00352664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352664 about?
NCT00352664 is a clinical study titled "The Effect of Donepezil on Sedation and Other Symptoms". Primary Objective: 1\. To determine the effectiveness of donepezil as compared to placebo for the management of opiate-induced sedation/drowsiness in patients with stable cancer pain Secondary Objectives: 1. To assess the side-effects in both groups of 1 week treatment of 5 mg donepezil and place...
What is the current status of trial NCT00352664?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2003-11. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00352664?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT00352664?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.